Cellevate has raised $4.0M in total across 1 funding round.
Cellevate's investors include Amadeus Capital Partners, Balderton Capital, BoxGroup, Craft Ventures, Daffy, FJ Labs, Homebrew, Kurma Partners, Makers Camp, Offline Ventures, #SecretFund, Y Combinator.
Cellevate is a Swedish biotech company founded in 2014 as a spin-out from NanoLund at Lund University, developing the proprietary Cellevat3d™ nanofiber-based platform for advanced cell culture in biopharmaceutical manufacturing.[1][2][3][4] This green deep-tech innovation produces microcarriers that mimic extracellular environments, enabling 3D cell growth with unprecedented surface area, reproducibility, and scalability for therapies like cell/gene treatments and vaccines.[1][4][5] Serving biopharma companies, it solves key upstream bioprocessing challenges—low yields, high costs, and sustainability issues—by boosting productivity (e.g., 13× higher vaccine yields, up to 85% cost reductions) while integrating from lab to commercial scale.[1][5] With $4.35M–$7.2M raised in seed funding (latest ~$3.55M–39M SEK in 2023), Cellevate shows strong growth momentum, planning Cellevat3d™ launches in 2024 and pre-launches like VAX for viral vectors.[2][3][4][5]
The idea for Cellevate emerged in 2011 at Lund University, when four engineering students collaborated with Professor Lars Montelius and Dr. [unspecified] at the world-leading NanoLund nanomaterials center.[3] This academic foundation led to the company's formal founding in 2014 as a spin-out, headquartered in Lund, Sweden's innovation hub.[1][2][3][4] Early focus centered on patenting a nanofiber manufacturing process to create 3D cell culture networks superior to traditional 2D monolayers, addressing limitations in biomanufacturing reproducibility and efficiency.[2][3] Pivotal traction came via seed funding from investors like Industrifonden, European Innovation Council, Onsight Ventures, and others, culminating in a 39M SEK round in October 2023 to fuel global commercialization.[2][3]
Cellevate rides the explosive growth in cell/gene therapies and vaccines, where demand for scalable biomanufacturing surges amid global needs for personalized medicine and pandemic preparedness.[1][5] Timing is ideal: post-COVID highlighted yield/cost bottlenecks in viral production, while nanofiber tech aligns with sustainability mandates and AI-driven biologics design trends.[2][5] Market forces like rising therapy volumes (e.g., Sanofi's AI biologics push) favor its efficiency gains, potentially enabling regional low-cost manufacturing and reshaping the $30B+ vaccines market by 2030.[2][5] As a deep-tech innovator, Cellevate influences the ecosystem by partnering with upstream solutions, accelerating commercialization for biopharma giants and startups alike.[1][3]
Cellevate is poised for breakout with 2024 product launches, leveraging recent funding to scale Cellevat3d™ globally and expand VAX-like variants for high-demand areas like gene therapy vectors.[3][4][5] Trends in sustainable bioprocessing, 3D culture adoption, and cost-pressured pharma will propel growth, potentially capturing share in a market hungry for 10x+ efficiency. Its influence may evolve from niche innovator to ecosystem enabler, powering next-gen therapies—watch for pilot adoptions and Series A as yields validate at scale, transforming biomanufacturing from factory bottleneck to competitive edge.[1][5]
Cellevate has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $4.0M Seed | Amadeus Capital Partners, Balderton Capital, BoxGroup, Craft Ventures, Daffy, FJ Labs, Homebrew, Kurma Partners, Makers Camp, Offline Ventures, #SecretFund, Y Combinator, Andreas Ehn, Elliot Shmukler, Loic Le Meur |
